Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.57 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.57 |
| ▸ | ITGAL | P20701 | 9/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020786 | 1.00 | HDAC1 (0.61) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL29381982 | 1.00 | HDAC1 (0.61) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL1020787 | 1.00 | HDAC1 (0.61) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| Hydrochloric Acid SCHEMBL29478485 | 0.99 | HDAC6 (0.60) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL23666454 | 0.93 | HDAC1 (0.65) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL17132276 | 0.91 | KMT2A (0.51) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL6763024 | 0.87 | HDAC1 (0.67) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL6763018 | 0.87 | HDAC1 (0.67) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL6759553 | 0.87 | ITGB2 (0.74) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL6759557 | 0.87 | ITGB2 (0.74) | HDAC1HDAC8HDAC6ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3481820-B1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11731977-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3872080-B1 | FUSED BICYCLIC SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023018795-A1 | NEP INHIBITORS FOR THE TREATMENT OF LAMINITIS | CURTAILS LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11572358-B2 | Solid forms of an sGC stimulator | CYCLERION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | CYCLERION THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100215779-A1 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | IRONWOOD PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100215779-A1 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | IRONWOOD PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100144864-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144864-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144864-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | GUCY1A2, GUCY1B2, GUCY1B1 | HDAC1 1630/4885HDAC8 1718/4885HDAC6 2190/4885 |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | HDAC1 2904/4885HDAC8 1828/4885HDAC6 1581/4885 |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | HDAC1 562/4885HDAC8 465/4885HDAC6 569/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | HDAC1 2904/4885HDAC8 1828/4885HDAC6 1581/4885 |
| US-11572358-B2 | Solid forms of an sGC stimulator | GUCY1A2, PRKG1, GUCY1A1 | HDAC1 3217/4885HDAC8 2953/4885HDAC6 3487/4885 |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | HDAC1 562/4885HDAC8 465/4885HDAC6 569/4885 |
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | GLS2, GPR119, PRKG1 | HDAC1 1951/4885HDAC8 1298/4885HDAC6 2435/4885 |
| US-20100215779-A1 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | SLC10A2, SLC10A1, SLC26A3 | HDAC1 2892/4885HDAC8 2603/4885HDAC6 1212/4885 |
| US-11731977-B2 | SGC stimulators | GUCY1A2, PRKG1, GMPS | HDAC1 3096/4885HDAC8 2441/4885HDAC6 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.